Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:50 UTC |
---|
Update Date | 2022-03-07 02:51:42 UTC |
---|
HMDB ID | HMDB0014659 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Albendazole |
---|
Description | Albendazole is only found in individuals that have used or taken this drug. It is a benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38)Albendazole causes degenerative alterations in the tegument and intestinal cells of the worm by binding to the colchicine-sensitive site of tubulin, thus inhibiting its polymerization or assembly into microtubules. The loss of the cytoplasmic microtubules leads to impaired uptake of glucose by the larval and adult stages of the susceptible parasites, and depletes their glycogen stores. Degenerative changes in the endoplasmic reticulum, the mitochondria of the germinal layer, and the subsequent release of lysosomes result in decreased production of adenosine triphosphate (ATP), which is the energy required for the survival of the helminth. Due to diminished energy production, the parasite is immobilized and eventually dies. |
---|
Structure | CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2 InChI=1S/C12H15N3O2S/c1-3-6-18-8-4-5-9-10(7-8)14-11(13-9)15-12(16)17-2/h4-5,7H,3,6H2,1-2H3,(H2,13,14,15,16) |
---|
Synonyms | Value | Source |
---|
(5-(Propylthio)-1H-benzimidazol-2-yl)carbamic acid methyl ester | ChEBI | 5-(Propylthio)-2-carbomethoxyaminobenzimidazole | ChEBI | Albenza | ChEBI | Eskazole | ChEBI | O-Methyl N-(5-(propylthio)-2-benzimidazolyl)carbamate | ChEBI | Proftril | ChEBI | Valbazen | ChEBI | Zentel | ChEBI | (5-(Propylthio)-1H-benzimidazol-2-yl)carbamate methyl ester | Generator | O-Methyl N-(5-(propylthio)-2-benzimidazolyl)carbamic acid | Generator | Albendazole armstrong brand | HMDB | Albendazole diba brand | HMDB | Albendazole pfizer brand | HMDB | Albendoral | HMDB | Armstrong brand OF albendazole | HMDB | SK And F62979 | HMDB | Albendazole sanicoopa brand | HMDB | Albendazole valdecasas brand | HMDB | Bendapar | HMDB | Digezanol | HMDB | Endoplus | HMDB | Fustery brand OF albendazole | HMDB | Hormona brand OF albendazole | HMDB | Liferpal brand OF albendazole | HMDB | Lurdex | HMDB | Mediamix V disthelm | HMDB | Metiazol | HMDB | Monohydrochloride, albendazole | HMDB | SK And F-62979 | HMDB | Sanicoopa brand OF albendazole | HMDB | Albendazole fustery brand | HMDB | Gascop | HMDB | Noé-socopharm brand OF albendazole | HMDB | Pfizer brand OF albendazole | HMDB | SmithKline beecham brand OF albendazole | HMDB | V Disthelm, mediamix | HMDB | Albendazole hormona brand | HMDB | Albendazole liferpal brand | HMDB | Albendazole monohydrochloride | HMDB | Albendazole noé-socopharm brand | HMDB | Bilutac | HMDB | Diba brand OF albendazole | HMDB | Disthelm | HMDB | Disthelm, mediamix V | HMDB | Noé socopharm brand OF albendazole | HMDB | SK And F 62979 | HMDB | Valdecasas brand OF albendazole | HMDB | Andazol | MeSH |
|
---|
Chemical Formula | C12H15N3O2S |
---|
Average Molecular Weight | 265.331 |
---|
Monoisotopic Molecular Weight | 265.088497429 |
---|
IUPAC Name | methyl N-[6-(propylsulfanyl)-1H-1,3-benzodiazol-2-yl]carbamate |
---|
Traditional Name | albendazol |
---|
CAS Registry Number | 54965-21-8 |
---|
SMILES | CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2 |
---|
InChI Identifier | InChI=1S/C12H15N3O2S/c1-3-6-18-8-4-5-9-10(7-8)14-11(13-9)15-12(16)17-2/h4-5,7H,3,6H2,1-2H3,(H2,13,14,15,16) |
---|
InChI Key | HXHWSAZORRCQMX-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as 2-benzimidazolylcarbamic acid esters. These are aromatic heteropolycyclic compounds that contain a carbamic acid ester group, which is N-linked to the C2-atom of a benzimidazole moiety. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Benzimidazoles |
---|
Sub Class | 2-benzimidazolylcarbamic acid esters |
---|
Direct Parent | 2-benzimidazolylcarbamic acid esters |
---|
Alternative Parents | |
---|
Substituents | - 2-benzimidazolylcarbamic acid ester
- Aryl thioether
- Thiophenol ether
- Alkylarylthioether
- Benzenoid
- Azole
- Imidazole
- Carbamic acid ester
- Heteroaromatic compound
- Carbonic acid derivative
- Thioether
- Azacycle
- Sulfenyl compound
- Organic nitrogen compound
- Hydrocarbon derivative
- Organic oxide
- Organosulfur compound
- Organooxygen compound
- Organonitrogen compound
- Organopnictogen compound
- Organic oxygen compound
- Carbonyl group
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | |
---|
Role | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 209 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.023 g/L | Not Available | LogP | 2.7 | Not Available |
|
---|
Experimental Chromatographic Properties | Experimental Collision Cross Sections |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Albendazole,1TMS,isomer #1 | CCCSC1=CC=C2N=C(N(C(=O)OC)[Si](C)(C)C)[NH]C2=C1 | 2371.1 | Semi standard non polar | 33892256 | Albendazole,1TMS,isomer #1 | CCCSC1=CC=C2N=C(N(C(=O)OC)[Si](C)(C)C)[NH]C2=C1 | 2253.2 | Standard non polar | 33892256 | Albendazole,1TMS,isomer #1 | CCCSC1=CC=C2N=C(N(C(=O)OC)[Si](C)(C)C)[NH]C2=C1 | 3263.5 | Standard polar | 33892256 | Albendazole,1TMS,isomer #2 | CCCSC1=CC=C2N=C(NC(=O)OC)N([Si](C)(C)C)C2=C1 | 2453.5 | Semi standard non polar | 33892256 | Albendazole,1TMS,isomer #2 | CCCSC1=CC=C2N=C(NC(=O)OC)N([Si](C)(C)C)C2=C1 | 2258.7 | Standard non polar | 33892256 | Albendazole,1TMS,isomer #2 | CCCSC1=CC=C2N=C(NC(=O)OC)N([Si](C)(C)C)C2=C1 | 3419.6 | Standard polar | 33892256 | Albendazole,2TMS,isomer #1 | CCCSC1=CC=C2N=C(N(C(=O)OC)[Si](C)(C)C)N([Si](C)(C)C)C2=C1 | 2408.8 | Semi standard non polar | 33892256 | Albendazole,2TMS,isomer #1 | CCCSC1=CC=C2N=C(N(C(=O)OC)[Si](C)(C)C)N([Si](C)(C)C)C2=C1 | 2353.9 | Standard non polar | 33892256 | Albendazole,2TMS,isomer #1 | CCCSC1=CC=C2N=C(N(C(=O)OC)[Si](C)(C)C)N([Si](C)(C)C)C2=C1 | 2893.8 | Standard polar | 33892256 | Albendazole,1TBDMS,isomer #1 | CCCSC1=CC=C2N=C(N(C(=O)OC)[Si](C)(C)C(C)(C)C)[NH]C2=C1 | 2585.4 | Semi standard non polar | 33892256 | Albendazole,1TBDMS,isomer #1 | CCCSC1=CC=C2N=C(N(C(=O)OC)[Si](C)(C)C(C)(C)C)[NH]C2=C1 | 2465.7 | Standard non polar | 33892256 | Albendazole,1TBDMS,isomer #1 | CCCSC1=CC=C2N=C(N(C(=O)OC)[Si](C)(C)C(C)(C)C)[NH]C2=C1 | 3262.9 | Standard polar | 33892256 | Albendazole,1TBDMS,isomer #2 | CCCSC1=CC=C2N=C(NC(=O)OC)N([Si](C)(C)C(C)(C)C)C2=C1 | 2657.9 | Semi standard non polar | 33892256 | Albendazole,1TBDMS,isomer #2 | CCCSC1=CC=C2N=C(NC(=O)OC)N([Si](C)(C)C(C)(C)C)C2=C1 | 2481.4 | Standard non polar | 33892256 | Albendazole,1TBDMS,isomer #2 | CCCSC1=CC=C2N=C(NC(=O)OC)N([Si](C)(C)C(C)(C)C)C2=C1 | 3415.6 | Standard polar | 33892256 | Albendazole,2TBDMS,isomer #1 | CCCSC1=CC=C2N=C(N(C(=O)OC)[Si](C)(C)C(C)(C)C)N([Si](C)(C)C(C)(C)C)C2=C1 | 2777.0 | Semi standard non polar | 33892256 | Albendazole,2TBDMS,isomer #1 | CCCSC1=CC=C2N=C(N(C(=O)OC)[Si](C)(C)C(C)(C)C)N([Si](C)(C)C(C)(C)C)C2=C1 | 2732.0 | Standard non polar | 33892256 | Albendazole,2TBDMS,isomer #1 | CCCSC1=CC=C2N=C(N(C(=O)OC)[Si](C)(C)C(C)(C)C)N([Si](C)(C)C(C)(C)C)C2=C1 | 3023.6 | Standard polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental GC-MS | GC-MS Spectrum - Albendazole GC-EI-TOF (Non-derivatized) | splash10-0zg0-1469000000-46c2b274ef14c131df22 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Albendazole GC-EI-TOF (Non-derivatized) | splash10-00dl-2920000000-8bfa1e52a364c2e1f3ac | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Albendazole GC-EI-TOF (Non-derivatized) | splash10-0zg0-1469000000-46c2b274ef14c131df22 | 2018-05-18 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Albendazole GC-EI-TOF (Non-derivatized) | splash10-00dl-2920000000-8bfa1e52a364c2e1f3ac | 2018-05-18 | HMDB team, MONA, MassBank | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Albendazole GC-MS (Non-derivatized) - 70eV, Positive | splash10-00vl-3960000000-6405beb97aaf7baeef1e | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Albendazole GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Albendazole LC-ESI-QFT , negative-QTOF | splash10-01q9-0090000000-672ce5296af7aee8b705 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Albendazole LC-ESI-QFT , negative-QTOF | splash10-001i-0390000000-5714d326ce05257dd82d | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Albendazole LC-ESI-QFT , negative-QTOF | splash10-000i-0910000000-e659044fe535a4187c4c | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Albendazole LC-ESI-QFT , negative-QTOF | splash10-000i-0900000000-a1c7141f3f860d69dca2 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Albendazole LC-ESI-QFT , negative-QTOF | splash10-000i-0900000000-96ae063a35ee4fe53390 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Albendazole LC-ESI-QFT , negative-QTOF | splash10-052r-2900000000-6103a7173b7b7689ee52 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Albendazole LC-ESI-QFT , negative-QTOF | splash10-0a4i-9600000000-7a4cee3070ee6f08b2cb | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Albendazole LC-ESI-QFT , negative-QTOF | splash10-0a4i-9200000000-109010056dd851a50ae4 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Albendazole LC-ESI-QFT , negative-QTOF | splash10-0a4i-9000000000-9f06e0952a63ae1312b3 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Albendazole LC-ESI-QFT , negative-QTOF | splash10-001r-0790000000-8ba2b09e2eefe111496f | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Albendazole LC-ESI-QTOF , positive-QTOF | splash10-001i-0290000000-db0e07ed437380dd7f56 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Albendazole LC-ESI-QTOF , positive-QTOF | splash10-0006-0910000000-80dd825626a5009e8924 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Albendazole LC-ESI-QTOF , positive-QTOF | splash10-052f-0900000000-ea3849a4ab993b24b4f0 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Albendazole LC-ESI-QFT , positive-QTOF | splash10-014i-0090000000-fe82219d2c01efc3494d | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Albendazole LC-ESI-QFT , positive-QTOF | splash10-00lr-0090000000-6d1f652e7ecf943d7400 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Albendazole LC-ESI-QFT , positive-QTOF | splash10-001i-0190000000-ab8f5993bbc5ebfcb04c | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Albendazole LC-ESI-QFT , positive-QTOF | splash10-000x-0950000000-0c5ca5956802aa312e11 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Albendazole LC-ESI-QFT , positive-QTOF | splash10-0006-0900000000-02e757b669a99db25608 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Albendazole LC-ESI-QFT , positive-QTOF | splash10-052f-0900000000-bef5aa7a328477b1c279 | 2017-09-14 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Albendazole 10V, Positive-QTOF | splash10-0uxr-1190000000-b3b5e0c1c81c186e0323 | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Albendazole 20V, Positive-QTOF | splash10-0a6u-6390000000-49710f98d2607932e74d | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Albendazole 40V, Positive-QTOF | splash10-01vo-6920000000-f7a76ee929303af68012 | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Albendazole 10V, Negative-QTOF | splash10-06si-5390000000-662c83573e8207d72065 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Albendazole 20V, Negative-QTOF | splash10-0a4i-5960000000-7fffbfea1f1e67fdbb9c | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Albendazole 40V, Negative-QTOF | splash10-01rx-9610000000-014e3ec45924170b49d0 | 2016-08-03 | Wishart Lab | View Spectrum |
NMR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
|
---|
General References | - Ramirez T, Benitez-Bribiesca L, Ostrosky-Wegman P, Herrera LA: In vitro effects of albendazole and its metabolites on the cell proliferation kinetics and micronuclei frequency of stimulated human lymphocytes. Arch Med Res. 2001 Mar-Apr;32(2):119-22. [PubMed:11343808 ]
- Haque A, Hollister WS, Willcox A, Canning EU: The antimicrosporidial activity of albendazole. J Invertebr Pathol. 1993 Sep;62(2):171-7. [PubMed:8228321 ]
- Oxberry ME, Reynoldson JA, Thompson RC: The binding and distribution of albendazole and its principal metabolites in Giardia duodenalis. J Vet Pharmacol Ther. 2000 Jun;23(3):113-20. [PubMed:11110097 ]
- Molina AJ, Merino G, Prieto JG, Real R, Mendoza G, Alvarez AI: Absorption and metabolism of albendazole after intestinal ischemia/reperfusion. Eur J Pharm Sci. 2007 May;31(1):16-24. Epub 2007 Feb 6. [PubMed:17350811 ]
|
---|